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Strengths and limitations of this study
 ► A systematic inventory of factors influencing access 
to transplantation will be accomplished without a 
predefined model to allow new information to arise.
 ► The perspectives of a diversity of stakeholders will 
be explored including those whose perspectives are 
rarely represented in literature, ie, policymakers and 
health insurers.
 ► Participating in the study will lead stakeholders to 
generate policy recommendations themselves, facil-
itating its consequent implementation.
 ► This study holds the promise of a more equal access 
to transplantation.
 ► The study is limited to the Dutch context.
AbStrACt
Introduction Unequal access to kidney transplantation 
is suggested, but no systematic inventory exists about 
factors influencing access to kidney transplantation. 
There is an absence of any research that has combined 
stakeholder perspectives along the complete trajectory 
of transplantation. The present qualitative study explores 
the contributing factors from the perspectives of multiple 
stakeholders in this trajectory, including patients, 
health professionals and health insurance and financial 
representatives in the Netherlands. Moreover, stakeholders 
will be invited to suggesting strategies and solutions for 
handling the facilitating and hindering factors found. By 
means of interaction, stakeholder groups will arrive at a 
consensus for new policymaking in the field of a Dutch 
transplantation care.
Methods and analysis The different stakeholders’ 
perspectives and possible solutions will be explored 
by interviewing in three phases. In the first phase, 
stakeholders’ group perspectives will be explored with 
individual interviews and focus group interviews without 
confrontation of views from other perspectives. In the 
second phase of focus group interviewing, perspectives 
will be confronted with the other stakeholders’ 
perspectives assessed. Finally, in the third phase, 
stakeholders will be invited to focus group discussions for 
suggesting solutions to overcome barriers and promote 
facilitators for improving access to transplantation. 
Approximately, groups from six to twelve participants per 
focus group and four to maximal six focus groups will be 
held per stakeholder, depending on the level of saturation, 
as prescribed by grounded theory. The interviews will be 
audio-recorded and transcribed verbatim, and qualitative 
data will be analysed according to the principles of 
grounded theory supported by using NVivo software.
Ethics and dissemination The Medical Ethical 
Committee of Erasmus MC, Rotterdam, The Netherlands, 
has approved this study. The results will be disseminated 
in peer-reviewed journals and major international 
conferences.
IntroduCtIon
Unequal access to kidney transplantation is 
suggested, but no systematic inventory exists 
about factors influencing access to kidney 
transplantation. There is an absence of any 
research that has combined stakeholder 
perspectives along the complete trajectory 
of transplantation.1–4 The present qualitative 
study explores the contributing factors from 
the perspectives of multiple stakeholders 
in this trajectory, including patients, health 
professionals and health insurance and finan-
cial representatives in the Netherlands. More-
over, stakeholders will be invited to suggesting 
strategies and solutions for handling the facil-
itating and hindering factors found. By means 
of interaction, stakeholder groups will arrive 
at a consensus for new policymaking in the 
field of a Dutch kidney transplantation care.
Kidney transplantation is promoted as the 
best option for renal replacement therapy 
for a significant group of the patients with 
end-stage renal disease (ESRD). The advan-
tages of kidney transplantation over dialysis 
treatment are longer patient survival5 6 and 
better quality of life.7 Further advantages of 
transplantation with a graft of a living donor 
compared with a graft of a deceased donor 
are often better graft quality and graft and 
patient survival, shorter waiting time, more 
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convenient scheduling of the operation and a real chance 
of pre-emptive transplantation.8–11 In the Netherlands, 
due to the scarcity of organs, pre-emptive transplantation 
is only possible in practice with an organ from a living 
donor. Compared with transplanted patients who under-
went a longer period of dialysis prior to transplantation, 
pre-emptive transplantation has additional medical 
advantages such as longer graft and patient survival,12–15 
less acute rejection16 as well as socioeconomic advan-
tages such as increased rates of patients continuing 
employment.17 Given the advantage of transplantation 
in general and pre-emptive transplantation in particular, 
it is remarkable that there are still so many patients on 
dialysis. Despite the fact that there are patients who are 
not eligible for transplantation, it could be that a group 
of patients on dialysis has never been screened for trans-
plantation or missed the opportunity of a pre-emptive 
transplantation. In this study, we set out to determine 
whether stakeholders believe that optimal treatment is 
already established or if there is a perceived inequality.
Equal access to transplantation can be defined in 
different ways. In this study, we will regard equality in 
terms of sociodemographic aspects such as migration 
background and age, medical aspects such as comorbidity 
or human leukocyte antigens (HLA) and blood type 
matching and timely aspects such as the work-up process 
of patients referred to transplantation screening or facili-
tating the pre-emptive trajectory.
The idea of unequal access to transplantation can be 
supported by the large prevalence of patients on dialysis 
waiting for a transplantation from a post-mortem dona-
tion.18 The problems of organ scarcity and waiting time 
became partly answered by transplantation with a graft of 
a living donor. Meanwhile, the percentage of living kidney 
donations in the Netherlands is among the highest in the 
world. It has been shown that many patients can find a 
living donor in their network if more support is given.19 
Special programme like our National kidney-exchange 
transplantation programme, AB0 incompatible and HLA 
incompatible transplantation and unspecified kidney 
donation have been established to overcome barriers for 
(matching) living donation. On one hand, these efforts 
might have resulted in a saturation of possibilities, and 
on the other hand still more action can be undertaken to 
facilitate living donation.
Another indication for inequality in access to transplan-
tation can be that there might be a group of patients who 
has been on dialysis for years, without even been screened 
or discussed for transplantation (with the transplanta-
tions centres). For the group of patients who has been on 
dialysis for a short period, a part might have missed the 
opportunity of pre-emptive transplantation. One of the 
goals of this investigation is to find the reasons why such 
non-optimal care persists and how it can be improved.
Observations as the ones above can also be found in 
the international literature. For instance, there is growing 
concern that access to transplantation is neither consis-
tent nor equitable.20 From the USA and the UK, racial 
or ethnical21 22 and age disparities23–25 within the patient 
population are reported as prominent barriers in access 
to kidney transplantation. Other potential barriers 
include lower socioeconomic status and poor education 
leading to a lack of knowledge.26
Also in the Dutch renal care setting, patients with a 
migration background and older patients can be identi-
fied as potentially vulnerable groups with respect to access 
to transplantation. A retrospective analysis of transplant 
recipients between 2000 and 2011 in our centre revealed 
that elderly patients and non-European patients were less 
likely to undergo living donor kidney transplantation.27 
This would also decrease their chance for pre-emptive 
transplantation. An analysis of the ethnic composition 
of our living donor population showed that there were 
significantly fewer ethnic minority living donors than 
would be expected based on the (patient) population 
composition.28 The PhD-thesis of M. Laging (2017) 
showed in a retrospective cohort study that the majority 
of younger patients (<25 years old) were transplanted 
for 6 years on the regional waiting list. The majority of 
them was transplanted with a graft from living a donor. 
In comparison with that only half of the patients in the 
age group >65 years old were transplanted during the 
same waiting time, from which half of the patients with 
a graft from a living donor. As a consequence, half of the 
older population died during the waiting time or had 
been definitely delisted. The patient group above 65 years 
old are a relevantly growing group among the patients 
with ESRD.18 Thus, there are several reports about not 
only unequal access between patients towards optimal 
care related to logistics and location, but also related to 
patients’ characteristics.
Next to patient-related factors, inequity in access to 
transplantation may be determined by professional- and 
system-related factors. For the latter, late referral29 30 
or the time between diagnosis of the renal disease and 
transplantation31 have been reported to influence access 
to kidney transplantation. Addressing the disparities in 
on time access to kidney transplantation including the 
perspectives of patients, healthcare providers and policy-
makers has recently been expressed as a research priority 
in organ transplantation in literature.32
Accordingly, the need for policy change and improve-
ment on different system-related factors in the Dutch 
transplantation care was supported during a recent 
national meeting organised by the Dutch Transplantation 
Foundation with medical professionals and donor organ-
isation and patient organisations supported.33 Hence, the 
focus of this study aligns with the need of professionals, 
donors and patients in The Netherlands. Further, quality 
indicators for the treatment of chronic kidney failure 
have been announced by Nefrovisie, the institution for 
quality management in nephrology in The Netherlands, 
together with Dutch Kidney Patient Association, Dutch 
Federation of Nephrology and Zorgverzekeraars Neder-
land, the umbrella organisation of 10 health insurers in 
The Netherlands. Pre-emptive kidney transplantation was 
4300.7802.430. Protected by copyright.
 o
n
 O
ctober 9, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032694 on 26 September 2019. Downloaded from 
3Kloss K, et al. BMJ Open 2019;9:e032694. doi:10.1136/bmjopen-2019-032694
Open access
named as one of the quality indicators. The additional 
question occurs if more patients with ESRD would be 
eligible for (pre-emptive) kidney transplantation and 
what the reasons would be for the limited implementa-
tion of the quality indicators currently.
There is speculation, but no systematic inventory has 
yet been accomplished which factors are responsible 
for the limited implementation of the quality indica-
tors in the treatment of chronic kidney failure and the 
disparity in access to best practice in renal replacement 
therapies. It depends, among other aspects, on referral 
of patients by nephrologists and dialysis centres, prefer-
ences of patients and subsequent adequate logistics of 
the transplantation work-up in transplant centres. This 
means that access to transplantation depends on multiple 
stakeholders, multiple motivations and incentives as well 
as interaction between stakeholders. Given this complex 
context, a systematic inventory into these factors can best 
rely on qualitative research methods.
Tong and colleagues34 highlighted the value of quali-
tative research in the field of transplantation, especially 
when it is about exploring barriers and inequities in 
access to transplantation. Earlier qualitative research 
on nephrologists’ and patients’ perspective on kidney 
transplantation has been done in Australia and New 
Zealand. It was demonstrated that physicians aim to 
optimise outcomes but feel conflicting interests between 
responsibility for the donor and recipient.35 A review of 
nephrologists’ perspective on patient referral, eligibility 
and screening showed that factors such as older age, 
ethnic background, socioeconomic status, comorbidities 
and non-adherence influence referral for transplanta-
tion.36 Patient-related factors that influence the choice 
of living donor transplantation have been reported to 
include prioritising own health, guilt and responsibility, 
ambivalence and uncertainty, seeking decisional valida-
tion, needing social support, and cautious donor recruit-
ment.37 38 More qualitative research would be helpful to 
get a better understanding of factors influencing time of 
referral and perceived inequality in access to transplan-
tation among patients and professionals. Moreover, the 
perspectives of policymakers and health insurers have yet 
to be investigated. More insight could help finding strat-
egies to facilitating better timing and a more equal access 
to optimal treatment.
objECtIvES
The aim of this project is to qualitatively explore factors 
that influence more optimal access to kidney transplan-
tation from the perspectives of different stakeholders in 
the Dutch setting, using grounded theory as the quali-
tative research method. Hence, perspectives of multiple 
stakeholders will be included, and therefore factors on 
different levels will be explored, namely psychological, 
clinical, ethical, social, economic and policy level. The 
final goal is to identify targets for policy changes and 
formulating strategies towards improvement of access to 
kidney transplantation in the Netherlands.
Hypothesis
Our hypothesis is that different stakeholders have different 
perspectives on whether there is indeed unequal access, 
and if such unequal access is assumed, stakeholders hold 
different views on how the access should be improved. Our 
hypothesis is further that in reflecting on the perspective 
of other stakeholders, participants will re-evaluate their 
point of views in order to reduce disparity. Moreover, in 
getting closer, they can and will formulate solutions on 
how to reduce unequal access to transplantation with 
respect to the views of other stakeholders.
MEtHodS And AnAlySIS
Patient and public involvement
Patients and most stakeholders were already involved in 
the study design. As the protocol was a grant proposal 
of the Dutch Kidney Foundation, the protocol was also 
judged by the patient reviewers. The study group is 
regularly advised by an advisory board, which includes 
representatives of most stakeholders groups involved: 
nephrologists, policymakers, patients and representatives 
of the kidney patient association and others. This board 
helps for instance in thinking about optimal logistical 
planning for the different groups to keep the research 
burden for participants as low as possible.
Study population
The study population will be organised in seven stake-
holder groups, namely patients (predialysis, pretrans-
plantation and post-transplantation groups), nephrology 
and transplantation nurses, social workers, nephrologists, 
health insurers and policymakers.
Eligible patients are adults (>18 years old) who have 1) 
been transplanted pre-emptively or non-pre-emptively 
but underwent dialysis for less than 1 year before trans-
plantation or who have 2) a kidney function of estimated 
glomerular filtration rate (eGFR) <15 mL/min and for 
whom initiation of dialysis can be expected within less 
than 3 months. Additionally, family members and (poten-
tial) donors of the kidney patients will be invited to take 
part in the patient focus groups.
The recruited professional groups will be nephrologists, 
nephrology and transplantation nurses as well as social 
workers, representatives of health insurances and poli-
cymakers working in the field of kidney transplantation 
throughout the Netherlands. Policymakers and health 
insurers will be representatives of national and regional 
institutions like Dutch Healthcare Authority, Dutch Trans-
plant Foundation, and Dutch Federation of Nephrology 
and National Healthcare Institute. Within all stakeholder 
groups, we will strive for sociodemographic variety among 
the participants to increase the transferability.39
recruitment
Patients will be recruited from outpatient clinics for 
nephrology from different treatment centres. The 
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eligibility of patients for the study will be assessed by their 
treating physician before patients are asked to participate 
in the study. The Dutch patient association and patient 
gatherings are further sources for approaching patients 
for participation.
Professionals will be recruited via the professional 
federations and institutions mentioned above or through 
different treatment centres, such as the university trans-
plantation centres, the regional hospitals and dialysis 
centres from different regions. The Dutch Federations 
of the distinct professional groups will be approached 
to assist us in reaching out to these professionals. Policy 
employees or governors from hospitals or governmental 
institutions, employees, representatives or delegates from 
health insurance companies will be identified through 
the Dutch Federations and nephrologists.
During the course of the interviews, we will also consult 
earlier participants to identify potential participants 
from the above-mentioned stakeholder groups (snowball 
sampling).
The senior researchers know a number of the partic-
ipants from their existing professional network, but a 
prior acquaintance with the participants was neither an 
inclusion nor exclusion criterion.
The prospective participants will receive a participant 
information letter with detailed information about the 
study and its accomplishment including audio-recording 
and voluntary participation as well as the informed 
consent form for signature. Participation is completely 
voluntary: subjects can leave the study at any time for any 
reason if they wish to do so without stating any reason and 
without any consequences for their medical treatment 
(for patients) or current function (for professionals). If a 
participant is willing to participate, a study interviewer will 
invite him or her by telephone or email for the interview.
Our aim is to reduce logistical barriers for all partici-
pants as much as possible. Therefore, the focus groups 
for patients will be held either in the hospital or in a 
remote location of choice, that is, a community centre. 
For healthcare professionals, individual interviews will 
be held at or close to their workplace. Focus group 
sessions will be held prior to or after regional nephrology 
or transplantation meetings. Adjunct to this, if neces-
sary, national congress meetings will be used as a venue 
to conduct the focus groups among healthcare profes-
sionals. For policy and health insurance representatives, 
we will strive to conduct the focus groups at their place of 
work. Researchers will try to match participants’ wishes 
with the feasibility of the study. In coordination with the 
participant, an appointment and location for the inter-
view will be assigned. It could be that different settings 
(location, number and type of co-participants, time of 
the year, etc.) might provoke different responses. We aim 
at minimising such variations and maximising the input 
that participants can and are willing to give. Therefore, 
the interviewers are trained and consequently (monthly) 
supervised to stimulate the responses/discussions in such 
a way that maximal saturation can be reached (ie, making 
sure that the participant can maximally elaborate on all 
presented/emerging topics).
dESIgn And ProCEdurE
Participants will be invited to take part in an individual 
interview or a focus group interview. The choice of 
using both group and individual interviews makes it 
possible to profit from the advantages of both methods: 
focus group interviews facilitate a broader exploration, 
whereas individual interviews allow a more in-depth 
exploration of topics raised.40 Moreover, an advantage 
of focus group interviews is that they allow insight into 
complex behaviour and motivation due to the interac-
tion happening during the focus groups.41 Additionally, 
applying both individual and focus group interviews will 
allow to test themes emerged from individual interviews 
in a broader range of respondents in the focus groups 
in short time.40 This will increase credibility of the study 
results.39
three phases
The interviews will be conducted in three phases. In the 
first phase, we will try to gather as much information 
as possible about factors that influence the access to 
transplantation according to the stakeholder groups by 
proceeding individual or focus group interviews. Then, 
focus groups will be organised separately for pre-dialysis 
and pretransplantation or post-transplantation patients, 
nephrologists, nurses, social workers, policymakers and 
insurance representatives. This homogeneity within the 
focus groups will ensure that participants are able to raise 
issues for discussion. Too much heterogeneity will inhibit 
discussion, especially when there are status distinctions 
between participants.42
In the second phase, focus groups will be held with 
the same stakeholder groups as in the first phase. In 
the beginning, stakeholders will be confronted with the 
outcomes of the first phase from their own but also from 
the other stakeholder groups. The objective of this phase 
is to let participants of each group reflect on the factors 
mentioned by their group but also by stakeholders from 
the other groups, on what factors they think influence 
accesses to transplantation. The expectation is that due 
to this iterative process, a more integrated model can be 
generated of the factors that can influence access to trans-
plantation, from different perspectives.
In the third phase, focus group sessions will be held with 
the same respective stakeholder groups from the previous 
two phases. Again, results from the previous phase will 
be presented in the beginning. The main objective of 
these focus groups will be to generate solutions for the 
integrated hindering or facilitating factors that emerged 
in the second phase. Participants who already took part 
in one phase will be invited to return to another phase 
of the study. New participants will also be welcomed to 
further prevent dropout.
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The three phases of this study will each encompass 
approximately 1 year. The first 1 or 2 months of each year 
will be used to write down a detailed script for conducting 
the focus groups. The last 1 or 2 months of each year 
will be used for transcribing and analysing the data. 
The remaining 8 to 10 months will be used for the most 
important part of this study, namely recruiting partic-
ipants for the interviews and conducting the individual 
interviews or focus groups, respectively. The fourth year 
will mainly be used for reporting and disseminating the 
outcomes.
data collection
Qualitative interviews
The individual interviews and the focus group interviews 
will be conducted by a moderator. These will be the junior 
researcher in Medical Psychology, a transplantation coor-
dinator, or a senior researcher in Medical Psychology, 
with assistance of one of the other colleagues who will 
take back-up paper and pencil notes and will monitor 
the discussed topics. All researchers have knowledge of 
qualitative methods based on previous research projects 
and training. The interviews will be audio-recorded after 
signed informed consent of the participant. If a partic-
ipant does not master the Dutch language, the use of a 
translated questionnaire and an interpreter for interviews 
will be considered.
The interviews will last about 45 min to 1.5 h for the 
individual interviews and about 2 to 3 h for focus groups, 
respectively. Participants will be asked what their attitudes, 
opinions, preferences and beliefs are regarding access to 
transplantation. The interviews will cover the topics clin-
ical, psychological, social, ethical, economic and policy factors 
influencing access to transplantation. The moderators 
will make use of an interview guide to monitor the topics 
discussed and to be able to offer prompts or sub-ques-
tions to a topic in case a participant does not raise a topic 
by himself or cannot come up spontaneously with any 
thoughts on one topic.
During the focus group sessions, the moderator will 
also use a flipchart to make notes for the group. The 
mediator will keep the discussion going and make sure 
that every participant gets the chance to contribute. At 
the end of a focus group session, the mediator will hold a 
debriefing, that is a summary of the raised issues. Finally, 
the participants will be asked to fill in a short question-
naire about their sociodemographic characteristics, their 
type of therapy (for patients) or their current function 
(for professionals). If necessary, the questionnaire is 
offered in other languages than Dutch.
Both types of interviews will be transcribed verbatim 
and the names of the participants will be replaced with 
identification codes to assure anonymity. If necessary, 
transcriptions will be translated into the Dutch language. 
We will not return the transcripts to participants for 
comments or corrections. There is no evidence that the 
use of certain checks improves research quality where the 
primary purpose of the research is theory development.43
data analysis
Data from the interviews will be analysed according to 
the principles of grounded theory.44 Using this inductive 
approach, a model or theory will be developed on the 
basis of the qualitative data generated. This approach is 
chosen as some perspectives of stakeholder groups have 
never been studied and because an integrated model 
based on the perspectives of the multiple stakeholders 
has never been formulated.
Two researchers will read through the interview tran-
scripts independently and data-driven codes will be 
assigned based on words and phrases.45 This process 
goes on until the two researchers separately worked 
through the whole transcript. The steps of open, axial 
and selective coding will be taken. Therefore, codes will 
be combined in order to generate a covering category. 
The two researchers then jointly cluster the derived cate-
gories into themes. Thereby, they identify the underlying 
uniformities of the categories and further sharpen the 
conceptual structure of each theme. During analysis, it is 
also important to measure the extensiveness (frequency, 
intensity and specificity) in which a topic is discussed. 
Consequently, a grid will be generated according to 
Miles and Huberman’s method in order to be able to 
compare the data between the groups.46 Within each 
theme, responses are evaluated across the different study 
groups to search for similarities and differences. Finally, 
the themes derived will be discussed in the research team. 
The qualitative software programme NVivo (v12) will be 
used during analysis to maximise efficiency.
Data generated by interviewing will be analysed until 
no new concepts or information arises, that is, data satu-
ration is reached following a general principle in qualita-
tive research.47 In other words, data saturation is reached 
when there is enough information to replicate the study,48 
and when further coding is no longer feasible.45 49 Hence, 
we will continue inclusion and data analysis until data 
saturation has been reached per stakeholder group. To 
monitor this continuously, each interview will be tran-
scribed as soon as possible and initial coding carried out 
before the subsequent interview. Data collection will cease 
for that specific stakeholder group if no new themes have 
emerged.49
Reporting of qualitative findings will adhere to the 
consolidated criteria for reporting qualitative research 
(COREQ).50
Sample size calculation
We did an effort to calculate the sample size on the basis 
of focus groups only. The focus groups will be organised 
homogeneous, thus, subdivided in the seven study groups. 
Four to six focus groups will be held per study group40 or 
until data saturation has been achieved.45 49 We will strive 
for a maximum of 12 participants per focus group, with a 
minimum of six participants.42 Hence, if four to six focus 
groups per stakeholder group are needed with seven 
study groups of stakeholders in each phase, we have to 
organise (4×7 =) 28 to (6×7 =) 42 focus group sessions per 
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phase. If six to twelve participants will participate in each 
focus group, (6×28 =) minimal 168 to (12×42 =) maximal 
504 participants will take part in this study. We aim to 
recruit 24 to 72 participants per study group. Considering 
the drop-out rate in the focus groups, approximately 
135 participants must be approached per study group51 
If saturation is reached earlier, less participants need to 
be recruited. Moreover, diversity among the stakeholder 
groups has to be considered. For instance, it is not yet 
known if 135 health insurers or health policymakers are 
indeed involved in kidney transplantation in a way rele-
vant for this investigation and if they are offering individ-
ually such diverse perspectives, that recruitment has to be 
continued to the maximum of the expected participants.
Status of the trial
The study started in May 2018 and participant recruit-
ment and initial data analyses are ongoing. The trial will 
last until December 2023.
EtHICS And dISSEMInAtIon
The Medical Ethical Committee of Erasmus MC, 
Rotterdam, The Netherlands, has approved this study, 
registered under MEC-2018–1473. Given the non-inter-
ventional nature of this study, a study registration was 
considered but deemed unnecessary by the Medical 
Research Involving Human Subjects Act. Participants 
will be given full study information (with a consideration 
period of minimum 1 week) and asked to provide written 
informed consent if they wish to participate.
The study will be conducted in accordance with the 
Declaration of Helsinki (Tokyo, Venice, Hong Kong and 
Somerset West amendments). A sequential identification 
number will be automatically attributed to each patient 
that has given consent to participate in the study. This 
number will identify the patient and must be included 
on all documents. Only the main researcher can link the 
code to the patient’s identity.
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